ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

Ilex Oncology Buys Symphar, Controls Drug For Bone Mets.

March 2, 2001

NCI To Pay 34 Percent Of Grants, At 155 Payline; $100 Million for Centers to Fund All Core Grants

January 29, 1988

Biomarker Test Outperforms PSA and Gleason Score in Study

July 26, 2013

Survey Finds. Bush Signs Stopgap Funding Measure;

October 5, 2007

Jackson Lab Win $9.5 Mil. Grant; Others Named

October 5, 1990

Interview: Von Eschenbach Says His Goal Is to Speed Development of Interventions

March 29, 2002